On-column refolding and purification of recombinant human interleukin-1 receptor antagonist (rHuIL-1ra) expressed as inclusion body in Escherichia coli

被引：7
|
作者：
Tan, HD
Dan, GP
Gong, HY
Cao, LJ
机构：
[1] Chinese Acad Sci, Dalian Inst Chem Phys, Dalian 116023, Peoples R China
[2] Yushui Biopharmaceut Co Ltd, Chongqing 200400, Peoples R China
来源：
BIOTECHNOLOGY LETTERS | 2005年 / 27卷 / 16期
关键词：
human interleukin-1 receptor antagonist; inclusion body; on-column refolding;
D O I：
10.1007/s10529-005-8655-5
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Recombinant human interleukin-1 receptor antagonist (rHuIL-1ra) was produced in E. coli as an inclusion body. rHuIL-1ra was purified to Over 98% purity by anion exchange chromatography after on-column refolding. The optimized processes produced more than 2 g pure refolded rHuIL-1ra per 1 l culture, corresponding to a 44% recovery, without an intermediate dialysis step. Refolded rHuIL-1ra had full biological activity with the MTT assay. An intramolecular disulfide linkage in the oxidized recombinant protein was suggested by data from HPLC and non-reducing SDS-PAGE.
引用
收藏
页码：1177 / 1182
页数：6
相关论文
共 50 条
  • [21] Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
    Bresnihan, B
    Alvaro-Gracia, JM
    Cobby, M
    Doherty, M
    Domljan, Z
    Emery, P
    Nuki, G
    Pavelka, K
    Rau, R
    Rozman, B
    Watt, I
    Williams, B
    Aitchison, R
    McCabe, D
    Musikic, P
    ARTHRITIS AND RHEUMATISM, 1998, 41 (12): : 2196 - 2204
  • [22] HUMAN RECOMBINANT INTERLEUKIN-1 RECEPTOR ANTAGONIST IN THE TREATMENT OF SEPSIS SYNDROME
    TOMPKINS, RG
    CRITICAL CARE MEDICINE, 1994, 22 (01) : 3 - 3
  • [23] Investigation on PEGylation strategy of recombinant human interleukin-1 receptor antagonist
    Yu, Pengzhan
    Zheng, Chunyang
    Chen, Jing
    Zhang, Guifeng
    Liu, Yongdong
    Suo, Xiaoyan
    Zhang, Guicai
    Su, Zhiguo
    BIOORGANIC & MEDICINAL CHEMISTRY, 2007, 15 (16) : 5396 - 5405
  • [24] Treatment with recombinant human interleukin-1 receptor antagonist (rhIL-1ra) may reduce synovial infiltration in rheumatoid arthritis (RA).
    Cunnane, G
    Madigan, A
    FitzGerald, O
    Bresnihan, B
    ARTHRITIS AND RHEUMATISM, 1996, 39 (09): : 1307 - 1307
  • [25] A 2-STEP PURIFICATION OF RECOMBINANT HUMAN INTERLEUKIN-1-BETA EXPRESSED IN ESCHERICHIA-COLI
    YEM, AW
    CURRY, KA
    TOMICH, CSC
    DEIBEL, MR
    IMMUNOLOGICAL INVESTIGATIONS, 1988, 17 (6-7) : 551 - 559
  • [26] EXPRESSION OF HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST (IL-1RA) IN TRANSGENIC MICE
    TRUMBAUER, ME
    CHEN, HY
    GRABIEC, CC
    HOFMANN, KJ
    ZHENG, H
    VANDERPLOEG, LHT
    SHAW, AR
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1994, : 289 - 289
  • [27] Population pharmacokinetics of recombinant interleukin-1 receptor antagonist (anakinra) in subjects with rheumatoid arthritis (RA).
    Yang, BB
    Frazier, J
    McCabe, D
    Young, JD
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S153 - S153
  • [28] The prospect of treating rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
    Bresnihan, B
    BIODRUGS, 2001, 15 (02) : 87 - 97
  • [29] KIDNEY AS A MAJOR CLEARANCE ORGAN FOR RECOMBINANT HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST
    KIM, DC
    REITZ, B
    CARMICHAEL, DF
    BLOEDOW, DC
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1995, 84 (05) : 575 - 580
  • [30] INITIAL CRYSTALLOGRAPHIC ANALYSIS OF A RECOMBINANT HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST PROTEIN
    CLANCY, LL
    FINZEL, BC
    YEM, AW
    DEIBEL, MR
    STRAKALAITIS, NA
    BRUNNER, DP
    SWEET, RM
    EINSPAHR, HM
    ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 1994, 50 : 197 - 201
12345